Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4,750 GBp
Change Today -80.50 / -1.67%
Volume 5.3M
AZN On Other Exchanges
Symbol
Exchange
New York
London
Stockholm
OTC US
As of 11:35 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Open
4,880 GBp
Previous Close
4,830 GBp
Day High
4,880 GBp
Day Low
4,664 GBp
52 Week High
04/23/15 - 4,906 GBp
52 Week Low
08/14/14 - 4,075 GBp
Market Cap
60.0B
Average Volume 10 Days
3.0M
EPS TTM
1.02 GBp
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
70.7x
Dividend
2.98 GBp
Dividend Yield
4.14%
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZN) Key Developments

AstraZeneca PLC Approves Adoption of New Articles of Association

AstraZeneca PLC at its Annual General Meeting on April 24, 2015, approved adoption of new articles of association of the company.

AstraZeneca PLC Elects Cori Bargmann as Director

AstraZeneca PLC has elected Cori Bargmann as a Director at the AGM held on 24 April 2015.

AstraZeneca PLC Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Year 2015

AstraZeneca PLC announced unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $6,057 million against $6,460 million a year ago. Operating profit was $933 million against $836 million a year ago. Profit before tax was $678 million against $638 million a year ago. Profit attributable to owners of the parent was $550 million against $504 million a year ago. Earnings per share basic and diluted were $0.44 against $0.40 a year ago. Net cash used in operating activities was $72 million compared with net cash from operating activities of $1,187 million a year ago. Purchase of property, plant and equipment was $227 million compared to $183 million a year ago. Purchase of intangible assets was $848 million compared to $545 million a year ago. Net debt as at March 31, 2015 was $6,373 million compared to $4,833 million as of March 31, 2014. Core operating profit was down 4% to $1,805 million. The Company reiterates the guidance for the year 2015. For the year 2015, the company’s total revenue is expected to decline by mid-single-digit percent at CER and core EPS is expected to increase by low single-digit percent at CER.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,749.50 GBp -80.50

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.07 USD +1.82
BASF SE €91.67 EUR +0.86
Biogen Inc $401.71 USD -28.57
Celgene Corp $118.71 USD +2.62
Eli Lilly & Co $71.58 USD -0.82
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 71.3x
Price/Sales 3.5x
Price/Book 5.4x
Price/Cash Flow 71.3x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.